We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Powered Pathology Can Radically Enhance Diagnostic Accuracy and Treatment Selection

By LabMedica International staff writers
Posted on 14 Mar 2022
Print article
Image: Collaboration to evolve use of AI-powered pathology algorithms (Photo courtesy of Cleveland Clinic)
Image: Collaboration to evolve use of AI-powered pathology algorithms (Photo courtesy of Cleveland Clinic)

A new collaborative effort will combine artificial intelligence (AI)-based platforms with clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics.

PathAI (Boston, MA, USA) and Cleveland Clinic (Cleveland, OH, USA) have entered into a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas. The collaboration will enable the digitization of hundreds of thousands of pathology specimens, creating millions of whole slide images across multiple disease areas. By linking this digital pathology data with clinical and molecular data, Cleveland Clinic and PathAI will have a rich multi-modal dataset to conduct research using PathAI’s technology platform and menu of pathology algorithms. The partnership also will provide educational opportunities for Cleveland Clinic faculty and trainees, with the goal of enabling the development and usage of AI-powered pathology diagnostics to improve patient care.

Cleveland Clinic will become an equity holder in PathAI as part of this agreement. PathAI will gain access to the digitized pathology slides to develop and improve its AI-powered algorithms, as well as clinical information for research and validation purposes all of which have been de-identified to protect patient privacy. Cleveland Clinic’s medical team will provide expertise to ensure algorithms are fit-for-purpose in both clinical and research settings.

“Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection,” said Dr. Brian Rubin, chair of Pathology and Laboratory Medicine Institute at Cleveland Clinic. “By doing this work, we’re able to maximize the value of machine learning for our patients and fuel deeper innovation that can result in better outcomes.”

“This exciting collaboration accelerates PathAI’s mission to provide precision pathology for everyone. Cleveland Clinic is the ideal partner, with its many leading clinicians, educators, and researchers who are committed to transforming patient care across disease areas,” said Dr. Andy Beck, CEO of PathAI. “We see an incredible opportunity to accelerate innovation in precision pathology and to use our strengths to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research.”

Related Links:
PathAI
Cleveland Clinic 

New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Automatic Hematology Analyzer
BF-7200Plus
New
Automated Nucleic Acid Extraction System
NuActor
New
Microplate Washer
STAT FAX 2600

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.